A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD

Inclusion Criteria: * Adult male or female over 55 years of age. Patient should be in sufficiently good health to reasonably expect survival for at least four years after treatment * Clinical findings consistent with advanced dry AMD * GA defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, and FA. * No evidence of current or prior choroidal neovascularization in the treated eye * The visual acuity (BCVA) of the eye to receive the transplant found to be eligible for trial based on study protocol * Electrophysiological findings consistent with advanced dry AMD. * Medically suitable to undergo vitrectomy and subretinal injection. * Medically suitable for general anesthesia or waking sedation, if needed. * Medically suitable for transplantation of an embryonic stem cell line Exclusion Criteria: * Presence of active or inactive CNV in the eye to be treated. * Presence or history of retinal dystrophy, retinitis pigmentosa, chorioretinitis, central serious choroidopathy, diabetic retinopathy or other retinal vascular or degenerative disease other than ARMD. * History of optic neuropathy. * Macular atrophy due to causes other than AMD. * Presence of glaucomatous optic neuropathy in the study eye, uncontrolled IOP, or use of two or more agents to control IOP (acetazolamide, beta blocker, alpha-1-agonist, prostaglandins, anhydrous carbonic inhibitors) * Cataract of sufficient severity likely to necessitate surgical extraction within 1 year. * History of retinal …